Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- EVER +28.9%, DOCN +17%, PRIM +11.6%, FARO +9%, XPRO +8.3%, TARS +6.5%, TILE +6%, AHCO +5.4%, VVX +5.3%, AROC +4.8%, SNN +4.7%, TREX +4.4%, DFH +4.3%, VNOM +3.9%, API +3.9%, WDS +3.3%, HLX +2.8%, AWI +2.7%, KDP +2.6%, GSHD +2.5%, FANG +2%, DKL +2%, KBR +1.9%, PRA +1.9%, MIDD +1.8%, STN +1.3%, BWXT +1.2%, FMS +1.1%, BEAM +1.1%, ADUS +0.9%
Other news:
- RDHL +9.3% (licenses RHB-102 for commercialization worldwide Excluding North America to Hyloris for up to $60 million in potential milestone payments plus royalties)
- YY +8.3% (Baidu acquires JOYY's (YY) live streaming business in China)
- NEOV +3.1% ($300 mln loan application passes Phase 2 of Department of Energy loan program)
- LLY +1.6% (launches additional Zepbound vial doses and offers new savings for self-pay patients)
- SONO +1.5% ($150 mln repurchase plan)
- BIDU +1.5% (Baidu acquires JOYY's (YY) live streaming business in China)
- SNY +1.2% (receives approval for Sarclisa in Japan for patients with newly diagnosed multiple myeloma)
- SB +1.1% (announces 3 mln share repurchase program)
- BBSI +1% (launches applicant tracking system)
- CHX +0.9% (entered into a definitive agreement to sell all of its equity interests in US Synthetic Corporation to LongRange Capital)
Analyst comments:
- PHG +2.2% (upgraded to Outperform from Neutral at Exane BNP Paribas)